An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis

Jayant A. Talwalkar, Patrick S. Kamath

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.

Original languageEnglish (US)
Pages (from-to)759-766
Number of pages8
JournalAmerican Journal of Medicine
Volume116
Issue number11
DOIs
StatePublished - Jun 1 2004

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis'. Together they form a unique fingerprint.

Cite this